| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00109-005-0688-7 |
| P8608 | Fatcat ID | release_blalgjtqgzdilojhbygu3fjfum |
| P698 | PubMed publication ID | 16133426 |
| P50 | author | Peter P Nawroth | Q88292204 |
| Per M Humpert | Q96350194 | ||
| Angelika Bierhaus | Q106836114 | ||
| Triantafyllos Chavakis | Q28054037 | ||
| P2093 | author name string | Bernd Arnold | |
| Michael Morcos | |||
| David M Stern | |||
| Thoralf Wendt | |||
| P2860 | cites work | CD36, serves as a receptor for advanced glycation endproducts (AGE) | Q77712197 |
| Antagonism of RAGE suppresses peripheral nerve regeneration | Q81089325 | ||
| RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways | Q81089332 | ||
| Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways | Q22010208 | ||
| RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides | Q22010236 | ||
| Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis | Q22254188 | ||
| Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins | Q24292994 | ||
| RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease | Q24314906 | ||
| Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily | Q24558912 | ||
| Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells | Q24563997 | ||
| Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis | Q24564718 | ||
| Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3 | Q28115196 | ||
| Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells | Q28138960 | ||
| HMG-1 as a late mediator of endotoxin lethality in mice | Q28139166 | ||
| Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB | Q28207628 | ||
| Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator | Q28263346 | ||
| S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) | Q28279641 | ||
| Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs | Q28290998 | ||
| Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice | Q28344139 | ||
| Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE) | Q28508886 | ||
| The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system | Q28567291 | ||
| RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages | Q28568915 | ||
| Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells | Q28570142 | ||
| Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding | Q28579193 | ||
| N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression | Q28645594 | ||
| The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site | Q28645645 | ||
| Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 | ||
| Function and activation of NF-kappa B in the immune system | Q29547790 | ||
| Toll-like receptors: critical proteins linking innate and acquired immunity | Q29615190 | ||
| Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma | Q30320422 | ||
| Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway | Q30445160 | ||
| cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. | Q30791560 | ||
| Negative consequences of glycation. | Q33849766 | ||
| The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation | Q33853348 | ||
| LPS and cytokine-activated endothelium | Q34113215 | ||
| The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses | Q34387881 | ||
| Diabetes and advanced glycation endproducts | Q34521835 | ||
| Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities | Q34557644 | ||
| Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. | Q34728855 | ||
| RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease | Q34836475 | ||
| Central role of RAGE-dependent neointimal expansion in arterial restenosis | Q34890522 | ||
| CD40 contributes to lethality in acute sepsis: in vivo role for CD40 in innate immunity | Q35011537 | ||
| Pattern recognition receptors: doubling up for the innate immune response | Q35036522 | ||
| Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders | Q35563889 | ||
| Chemical modification of proteins by lipids in diabetes | Q35576075 | ||
| HMGB1 in Sepsis | Q35585048 | ||
| Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease | Q36771851 | ||
| Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer | Q37384492 | ||
| High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules | Q37529086 | ||
| N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth | Q38290193 | ||
| A sustained reduction in IkappaB-beta may contribute to persistent NF-kappaB activation in human endothelial cells | Q38355620 | ||
| Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury | Q38359414 | ||
| Role of Escherichia coli curli operons in directing amyloid fiber formation | Q39620298 | ||
| RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice | Q40251711 | ||
| Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products | Q40304611 | ||
| S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. | Q40574504 | ||
| Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). | Q40636638 | ||
| Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. | Q40653176 | ||
| Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system | Q40668935 | ||
| Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. | Q40730866 | ||
| The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells | Q40766569 | ||
| Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion | Q40803274 | ||
| Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line | Q40806119 | ||
| Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response | Q40899986 | ||
| Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | Q41009444 | ||
| Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. | Q41893958 | ||
| The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment | Q42037633 | ||
| Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose | Q42070713 | ||
| RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy | Q42263637 | ||
| Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products | Q42440103 | ||
| Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease | Q42790513 | ||
| Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. | Q43565214 | ||
| Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. | Q43633661 | ||
| Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. | Q43786750 | ||
| Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs | Q44328949 | ||
| The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. | Q44432075 | ||
| Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products | Q44499434 | ||
| Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis | Q44815233 | ||
| High mobility group 1 B-box mediates activation of human endothelium | Q45182292 | ||
| Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products | Q47231228 | ||
| Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. | Q47785594 | ||
| AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept | Q47864019 | ||
| Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques | Q48584185 | ||
| Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress | Q50180621 | ||
| Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? | Q53258066 | ||
| Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. | Q53348339 | ||
| Regulation of cell migration by amphoterin. | Q55476224 | ||
| Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis | Q57909992 | ||
| Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases | Q59084980 | ||
| Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE | Q63433994 | ||
| Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface | Q67854285 | ||
| Expression of receptors for advanced glycosylated end-products in renal disease | Q70894957 | ||
| The dark side of glucose | Q71563592 | ||
| The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide | Q72331984 | ||
| I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B | Q72571349 | ||
| Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation | Q73010823 | ||
| Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease | Q73108179 | ||
| Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells | Q73674097 | ||
| Chemical modification of proteins by methylglyoxal | Q77659598 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 876-886 | |
| P577 | publication date | 2005-08-24 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Understanding RAGE, the receptor for advanced glycation end products | |
| P478 | volume | 83 |
| Q45895657 | -374 T/A polymorphism in RAGE gene is associated with onset of diabetes mellitus, atherosclerosis, and renal dysfunction in patients with hypertension |
| Q55026978 | 1,25-Dihydroxyvitamin D increases the gene expression of enzymes protecting from glucolipotoxicity in peripheral blood mononuclear cells and human primary endothelial cells. |
| Q35682226 | 2245G/A polymorphism of the receptor for advanced glycation end-products (RAGE) gene is associated with diabetic retinopathy in the Malaysian population. |
| Q93016458 | A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection |
| Q47794313 | A model of chronic diabetic polyneuropathy: benefits from intranasal insulin are modified by sex and RAGE deletion |
| Q40516938 | A monoclonal antibody against the receptor for advanced glycation end products attenuates inflammatory and neuropathic pain in the mouse |
| Q28261647 | A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease |
| Q97880172 | A negative association of dietary advanced glycation end products with obesity and body composition in Iranian adults |
| Q36447090 | A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC |
| Q42924090 | A novel hypothesis: up-regulation of HO-1 by activation of PPARγ inhibits HMGB1-RAGE signaling pathway and ameliorates the development of ALI/ARDS. |
| Q37986418 | A novel improved therapy strategy for diabetic nephropathy: targeting AGEs |
| Q36162053 | A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation |
| Q28507626 | A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis |
| Q90483949 | A single high-fat meal alters human soluble RAGE profiles and PBMC RAGE expression with no effect of prior aerobic exercise |
| Q48103881 | ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes |
| Q51747235 | AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease. |
| Q37326771 | AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. |
| Q55381313 | Abnormal expressions of AGEs, TGF-β1, BDNF and their receptors in diabetic rat colon-Associations with colonic morphometric and biomechanical remodeling. |
| Q37981048 | Accessory molecules for Toll-like receptors and their function |
| Q35159141 | Accumulation of advanced glycation end-products and activation of the SCAP/SREBP Lipogenetic pathway occur in diet-induced obese mouse skeletal muscle |
| Q35086500 | Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression |
| Q91640927 | Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects |
| Q28550923 | Advanced Glycation End Products Impair Voltage-Gated K+ Channels-Mediated Coronary Vasodilation in Diabetic Rats |
| Q28591845 | Advanced glycated end-products affect HIF-transcriptional activity in renal cells |
| Q37362121 | Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia |
| Q37520014 | Advanced glycation end products (AGE) and diabetes: cause, effect, or both? |
| Q37433970 | Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis |
| Q37149382 | Advanced glycation end products and diabetic foot disease |
| Q34542291 | Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption |
| Q37454060 | Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells |
| Q27024641 | Advanced glycation end products play adverse proinflammatory activities in osteoporosis |
| Q36974285 | Advanced glycation end products, diabetes and ageing. |
| Q36643573 | Advanced glycation end products: Key players in skin aging? |
| Q38081119 | Advanced glycation end products: role in pathology of diabetic cardiomyopathy |
| Q40741859 | Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats |
| Q38695799 | Advanced glycation end-products and Porphyromonas gingivalis lipopolysaccharide increase calprotectin expression in human gingival epithelial cells. |
| Q36842527 | Advanced glycation endproducts and their receptor in different body compartments in COPD |
| Q93128949 | Advanced glycation endproducts produced by in vitro glycation of type I collagen modulate the functional and secretory behavior of dorsal root ganglion cells cultivated in two-dimensional system |
| Q45317055 | Advanced glycosylation endproduct receptor signaling |
| Q37325552 | Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors |
| Q90242674 | Ager-CreERT2: A New Genetic Tool for Studying Lung Alveolar Development, Homeostasis, and Repair |
| Q36542733 | Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. |
| Q33817302 | Alarmins, inflammasomes and immunity |
| Q39246681 | All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses |
| Q35530622 | Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats |
| Q26778149 | Alzheimer's Disease: Mechanism and Approach to Cell Therapy |
| Q60934040 | Analysis of Protein Oxidative Modifications in Follicular Fluid from Fertile Women: Natural Versus Stimulated Cycles |
| Q40135757 | Anthocyanins Reversed D-Galactose-Induced Oxidative Stress and Neuroinflammation Mediated Cognitive Impairment in Adult Rats |
| Q28075161 | Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand? |
| Q92929381 | Anti-Inflammatory Effect of an Apigenin-Maillard Reaction Product in Macrophages and Macrophage-Endothelial Cocultures |
| Q38720019 | Anti-glycation and anti-oxidative effects of a phenolic-enriched maple syrup extract and its protective effects on normal human colon cells. |
| Q37873482 | Anti-inflammatory therapy for diabetic retinopathy. |
| Q40858020 | Antibodies to age-β2 glycoprotein I in patients with anti-phospholipid antibody syndrome. |
| Q47110686 | Antioxidative Effects of Natural Products on Diabetic Cardiomyopathy. |
| Q26770022 | Association between HMGB1 and COPD: A Systematic Review |
| Q42228844 | Association between fecal S100A12 concentration and histologic, endoscopic, and clinical disease severity in dogs with idiopathic inflammatory bowel disease |
| Q33619918 | Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase |
| Q80253430 | Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes |
| Q35727237 | Association between the Advanced Glycosylation End Product-Specific Receptor Gene and Cardiovascular Death in Older Men |
| Q35545467 | Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies |
| Q37188104 | Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy |
| Q35064231 | Associations between maternal and infant morbidities and sRAGE within the first week of life in extremely preterm infants |
| Q36909193 | Atherosclerosis and the Hypercholesterolemic AGE-RAGE Axis |
| Q36179624 | Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling |
| Q38232036 | Baking, ageing, diabetes: a short history of the Maillard reaction |
| Q37069537 | Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis |
| Q38797428 | Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease |
| Q35958312 | Biomarkers in acute lung injury. |
| Q45979790 | Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. |
| Q24318378 | Both Ca2+ and Zn2+ are essential for S100A12 protein oligomerization and function |
| Q36187954 | Bovine lactoferrin free of lipopolysaccharide can induce a proinflammatory response of macrophages |
| Q90122056 | Breviscapine exerts neuroprotective effects through multiple mechanisms in APP/PS1 transgenic mice |
| Q38542045 | Can insulin signaling pathways be targeted to transport Aβ out of the brain? |
| Q33890233 | Carboxylated N-glycans on RAGE promote S100A12 binding and signaling |
| Q43013056 | Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. |
| Q39083457 | Cell culture condition-dependent impact of AGE-rich food extracts on kinase activation and cell survival on human fibroblasts |
| Q30583559 | Cell migration to CXCL12 requires simultaneous IKKα and IKKβ-dependent NF-κB signaling |
| Q83232804 | Cell non-autonomous functions of S100a4 drive fibrotic tendon healing |
| Q37934954 | Cell signaling and receptors in toxicity of advanced glycation end products (AGEs): α-dicarbonyls, radicals, oxidative stress and antioxidants |
| Q36119506 | Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation |
| Q92813722 | Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding |
| Q38851823 | Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda |
| Q24310573 | Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15 |
| Q35228472 | Chronic alcohol administration causes expression of calprotectin and RAGE altering the distribution of zinc ions in mouse testis |
| Q42171678 | Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy |
| Q35124150 | Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products. |
| Q54941926 | Clinical and Biological Predictors of Plasma Levels of Soluble RAGE in Critically Ill Patients: Secondary Analysis of a Prospective Multicenter Observational Study. |
| Q37556492 | Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE |
| Q58728690 | Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs |
| Q33671771 | Co-expression of BirA with biotin bait achieves in vivo biotinylation of overexpressed stable N-glycosylated sRAGE in transgenic silkworms |
| Q94554347 | Comprehensive analysis of posttranslational protein modifications in aging of subcellular compartments |
| Q43465717 | Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats |
| Q38853305 | Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study |
| Q38150990 | Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention? |
| Q90662894 | Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide |
| Q38051199 | Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast |
| Q28484372 | Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats |
| Q34409300 | Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling |
| Q42182823 | Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro |
| Q36252773 | Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress |
| Q38297265 | Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo |
| Q24564765 | Damage associated molecular pattern molecules |
| Q36165681 | Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1 |
| Q38106874 | Damage-associated molecular patterns and their receptors in upper airway pathologies |
| Q90707412 | Damage-associated molecular patterns in trauma |
| Q38173348 | Danger signals in the initiation of the inflammatory response after myocardial infarction |
| Q55355541 | Danger signals in trauma. |
| Q30380000 | Dangers within: DAMP responses to damage and cell death in kidney disease. |
| Q80579683 | Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome |
| Q51877869 | Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. |
| Q57549422 | Decreased plasma sRAGE levels in COPD: influence of oxygen therapy |
| Q61512392 | Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes |
| Q35790418 | Dendritic cells as danger-recognizing biosensors |
| Q44298630 | Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation |
| Q38890935 | Design, synthesis, and biological evaluation of pyrimidine-2-carboxamide analogs: investigation for novel RAGE inhibitors with reduced hydrophobicity and toxicity |
| Q90720617 | Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
| Q42021514 | Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I |
| Q38901757 | Diabetes mellitus and the skin. |
| Q91583464 | Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences |
| Q33711031 | Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function |
| Q38919955 | Diabetes-induced mechanophysiological changes in the esophagus. |
| Q39427195 | Diabetes-induced mechanophysiological changes in the small intestine and colon |
| Q37072018 | Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent? |
| Q39427655 | Dietary Advanced Glycation End Products and Cardiometabolic Risk |
| Q99555773 | Dietary Advanced Glycation Endproducts and the Gastrointestinal Tract |
| Q33616876 | Dietary Sugars and Endogenous Formation of Advanced Glycation Endproducts: Emerging Mechanisms of Disease |
| Q35670859 | Dietary advanced glycation end products and aging |
| Q48012355 | Dietary advanced glycation end products modify gut microbial composition and partially increase colon permeability in rats |
| Q38077658 | Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. |
| Q42794385 | Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury |
| Q37262909 | Dietary consumption of meat, fat, animal products and advanced glycation end-products and the risk of Barrett's oesophagus |
| Q33932632 | Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial |
| Q33831129 | Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells |
| Q53490356 | Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. |
| Q26744644 | Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases |
| Q38542827 | Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease |
| Q34531584 | Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis |
| Q24632710 | Does accumulation of advanced glycation end products contribute to the aging phenotype? |
| Q26765800 | Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox? |
| Q35809946 | Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics |
| Q37578319 | Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease |
| Q33611402 | Effect of TTP488 in patients with mild to moderate Alzheimer's disease |
| Q38250741 | Effect of advanced glycation end product intake on inflammation and aging: a systematic review. |
| Q38588208 | Effect of diet-derived advanced glycation end products on inflammation. |
| Q54233906 | Effect of selected gastrointestinal parasites and viral agents on fecal S100A12 concentrations in puppies as a potential comparative model. |
| Q36248172 | Effect of tangweian jianji on upper gastrointestinal remodeling in streptozotocin-induced diabetic rats |
| Q48747347 | Effect of transient cerebral ischemia on the expression of receptor for advanced glycation end products (RAGE) in the gerbil hippocampus proper |
| Q41991828 | Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung injury. |
| Q57659960 | Effects of Resveratrol on Receptor for Advanced Glycation End Products (RAGE) Expression and Oxidative Stress in the Liver of Rats with Type 2 Diabetes |
| Q33746869 | Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis |
| Q51648184 | Effects of a recruitment maneuver on plasma levels of soluble RAGE in patients with diffuse acute respiratory distress syndrome: a prospective randomized crossover study. |
| Q43101263 | Effects of dietary arginine on inflammatory mediator and receptor of advanced glycation endproducts (RAGE) expression in rats with streptozotocin-induced type 2 diabetes |
| Q82746070 | Effects of glutamine supplementation on oxidative stress-related gene expression and antioxidant properties in rats with streptozotocin-induced type 2 diabetes |
| Q35953547 | Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis |
| Q46174114 | Effects of puerarin on receptor for advanced glycation end products in nephridial tissue of streptozotocin-induced diabetic rats |
| Q49610444 | Elevated donor plasminogen activator inhibitor-1 levels and the risk of primary graft dysfunction |
| Q37270915 | Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs |
| Q38966308 | Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients. |
| Q27015835 | Emerging roles for HMGB1 protein in immunity, inflammation, and cancer |
| Q42176457 | Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. |
| Q37229916 | Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer |
| Q37906759 | Essential role of high-mobility group box proteins in nucleic acid-mediated innate immune responses |
| Q33509786 | Estrogen replacement therapy in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules via a RAGE-related process |
| Q45718642 | Evidence for polygenic adaptation to pathogens in the human genome |
| Q47579007 | Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats |
| Q33639120 | Exercise and Glycemic Control: Focus on Redox Homeostasis and Redox-Sensitive Protein Signaling |
| Q47877902 | Expression and purification of the extracellular domains of human glycoprotein VI (GPVI) and the receptor for advanced glycation end products (RAGE) from Rattus norvegicus in Leishmania tarentolae. |
| Q39743331 | Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease |
| Q94544471 | Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? |
| Q88899708 | Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway |
| Q36647396 | Free radicals in aging: causal complexity and its biomedical implications |
| Q37661169 | Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis |
| Q47101820 | Functional Effects of Alagebrium (ALT-711)-Isolated Rat Carotid Artery |
| Q33525563 | Functional status of peripheral blood T-cells in ischemic stroke patients |
| Q37001259 | Functions of S100 proteins. |
| Q38258947 | Galectin-3: an emerging all-out player in metabolic disorders and their complications |
| Q38763332 | Gamma-linolenic acid ameliorated glycation-induced memory impairment in rats. |
| Q57175176 | Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration |
| Q36179583 | Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury |
| Q45001439 | Genotyping of -374A/T, -429A/G, and 63 bp Ins/del polymorphisms of RAGE by rapid one-step hexaprimer amplification refractory mutation system polymerase chain reaction in breast cancer patients. |
| Q39397467 | Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma. |
| Q36913552 | Glucitol-core containing gallotannins inhibit the formation of advanced glycation end-products mediated by their antioxidant potential |
| Q38953440 | Glycated albumin: from biochemistry and laboratory medicine to clinical practice. |
| Q37465801 | HMGB1 Promotes Intraoral Palatal Wound Healing through RAGE-Dependent Mechanisms |
| Q37199557 | HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. |
| Q40058870 | HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration |
| Q92896599 | HMGB1 enhances AGE-mediated VSMC proliferation via an increase in 5-LO-linked RAGE expression |
| Q34622835 | HMGB1 in health and disease |
| Q36919024 | HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption |
| Q42347142 | HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-κB signaling pathway |
| Q33381657 | HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk |
| Q41606893 | HMGB1/Advanced Glycation End Products (RAGE) does not aggravate inflammation but promote endogenous neural stem cells differentiation in spinal cord injury |
| Q36827934 | HMGB1: a signal of necrosis |
| Q92889825 | Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study |
| Q28577024 | High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues |
| Q38210271 | High-mobility group box 1 (HMGB1) in childhood: from bench to bedside |
| Q37206315 | High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease |
| Q34170847 | High-mobility group protein box-1 and its relevance to cerebral ischemia |
| Q47699459 | Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair |
| Q39700115 | Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. |
| Q35562286 | Human muscle satellite cells show age-related differential expression of S100B protein and RAGE |
| Q41461919 | Hyperferritinemia and markers of inflammation and oxidative stress in the cord blood of HIV-exposed, uninfected (HEU) infants |
| Q53218782 | IL-1β enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release. |
| Q37305013 | IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies |
| Q89883961 | Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach |
| Q51031454 | Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. |
| Q57110548 | Immunomodulation by Processed Animal Feed: The Role of Maillard Reaction Products and Advanced Glycation End-Products (AGEs) |
| Q51752708 | Immunomodulation by a combination of nitric oxide and glucocorticoids in a human endotoxin model |
| Q92059098 | Impact of RAGE polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long-term survival |
| Q50223052 | Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes |
| Q47548856 | Impairment of Novel Object Recognition Memory and Brain Insulin Signaling in Fructose- but Not Glucose-Drinking Female Rats |
| Q57050209 | In Utero Heat Stress Alters the Offspring Epigenome |
| Q42235792 | Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies |
| Q42414162 | Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products |
| Q45274141 | Increased receptor for advanced glycation endproducts immunocontent in the cerebral cortex of vitamin A-treated rats |
| Q34364237 | Induction of RAGE shedding by activation of G protein-coupled receptors |
| Q37911285 | Inflammation and diabetic retinal microvascular complications |
| Q22241893 | Inflammation and insulin resistance |
| Q37705110 | Inflammation-associated S100 proteins: new mechanisms that regulate function. |
| Q59049799 | Inflammatory Response in Patients under Coronary Artery Bypass Grafting Surgery and Clinical Implications: A Review of the Relevance of Dexmedetomidine Use |
| Q36878348 | Inflammatory markers associated with osteoarthritis after destabilization surgery in young mice with and without Receptor for Advanced Glycation End-products (RAGE) |
| Q64056217 | Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation |
| Q52144777 | Inhibition of the Receptor for Advanced Glycation End-Products (RAGE) Attenuates Neuroinflammation While Sensitizing Cortical Neurons Towards Death in Experimental Subarachnoid Hemorrhage. |
| Q93024896 | Inhibition of the Receptor for Advanced Glycation End-Products in Acute Respiratory Distress Syndrome: A Randomised Laboratory Trial in Piglets |
| Q34043446 | Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected] |
| Q89180802 | Inorganic Polyphosphate Amplifies High Mobility Group Box 1-Mediated Von Willebrand Factor Release and Platelet String Formation on Endothelial Cells |
| Q35582599 | Inorganic polyphosphate elicits pro-inflammatory responses through activation of the mammalian target of rapamycin complexes 1 and 2 in vascular endothelial cells |
| Q51043667 | Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone. |
| Q27001177 | Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms |
| Q28577725 | Internalization of the receptor for advanced glycation end products (RAGE) is required to mediate intracellular responses |
| Q42579440 | Intracellular and Extracellular Effects of S100B in the Cardiovascular Response to Disease |
| Q30317651 | Intraoperative sRAGE kinetics. A new age-related outcome predictor of cardiac surgery |
| Q37595925 | Investigating wild berries as a dietary approach to reducing the formation of advanced glycation endproducts: chemical correlates of in vitro antiglycation activity |
| Q38260264 | Investigation of phosphoproteome in RAGE signaling |
| Q28570305 | Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)--and amyloid beta 1-42-induced signal transduction in glial cells |
| Q42277371 | Levels of S100B protein drive the reparative process in acute muscle injury and muscular dystrophy |
| Q40866184 | Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases |
| Q46595652 | Limited role of the receptor for advanced glycation end products during Streptococcus pneumoniae bacteremia. |
| Q64883415 | Long-term administration of melatonin attenuates neuroinflammation in the aged mouse brain. |
| Q34311706 | Longistatin in tick saliva blocks advanced glycation end-product receptor activation |
| Q28276929 | Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types |
| Q36575194 | Lung inflammation biomarkers and lung function in children chronically exposed to arsenic |
| Q92615014 | MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients |
| Q38776099 | Maillard reaction in food allergy: Pros and cons |
| Q38770084 | Markers of immune-mediated inflammation in the brains of young adults and adolescents with type 1 diabetes and fatal diabetic ketoacidosis. Is there a difference? |
| Q92163626 | Maternal Consumption of a Diet Rich in Maillard Reaction Products Accelerates Neurodevelopment in F1 and Sex-Dependently Affects Behavioral Phenotype in F2 Rat Offspring |
| Q42089443 | Measurement of Lens Autofluorescence for Diabetes Screening |
| Q36454380 | Mechanism Investigation of the Improvement of Chang Run Tong on the Colonic Remodeling in Streptozotocin-Induced Diabetic Rats |
| Q36864025 | Mechanisms of disease: a 'DAMP' view of inflammatory arthritis |
| Q38330759 | Mechanisms of distal axonal degeneration in peripheral neuropathies. |
| Q46813751 | Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model |
| Q35141196 | Mesona Chinensis Benth extract prevents AGE formation and protein oxidation against fructose-induced protein glycation in vitro |
| Q50482190 | Methylglyoxal concentrations differ in standard and washed neonatal packed red blood cells. |
| Q34854364 | Methylprednisolone stiffens aortas in lipopolysaccharide-induced chronic inflammation in rats |
| Q41014561 | Microglia function in Alzheimer's disease |
| Q46102290 | Milk Intake at Midlife and Cognitive Decline over 20 Years. The Atherosclerosis Risk in Communities (ARIC) Study |
| Q34557348 | Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy |
| Q38846666 | Molecular characterization of glycation-associated skin ageing: an alternative skin model to study in vitro antiglycation activity of topical cosmeceutical and pharmaceutical formulations. |
| Q38108373 | Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. |
| Q100751507 | Molecular phenotyping of oxidative stress in diabetes mellitus with point-of-care NMR system |
| Q38096444 | Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. |
| Q45817707 | Morphological adaptation of muscle collagen and receptor of advanced glycation end product (RAGE) in osteoarthritis patients with 12 weeks of resistance training: influence of anti-inflammatory or glucosamine treatment. |
| Q37564063 | Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications |
| Q38140624 | Natural compounds with anti-ageing activity |
| Q50958699 | Neurodegenerative Markers are Increased in Postmortem BA21 Tissue from African Americans with Alzheimer's Disease. |
| Q91773901 | Neuroinflammation: friend and foe for ischemic stroke |
| Q37977251 | Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain |
| Q42870334 | Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice |
| Q35559895 | Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease |
| Q36330297 | Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease |
| Q35719575 | New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients |
| Q37596871 | Nicousamide protects kidney podocyte by inhibiting the TGFβ receptor II phosphorylation and AGE-RAGE signaling |
| Q34604583 | Novel Inhibitory Effects of Glycyrrhizic Acid on the Accumulation of Advanced Glycation End Product and Its Receptor Expression |
| Q28286769 | Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function |
| Q24170228 | Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes |
| Q37070169 | Ovariectomy increases neuronal amyloid-beta binding alcohol dehydrogenase level in the mouse hippocampus |
| Q36084076 | Overexpression of human HSP27 protects sensory neurons from diabetes |
| Q33999811 | Overexpression of receptor for advanced glycation end products and high-mobility group box 1 in human dental pulp inflammation |
| Q37741560 | Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease |
| Q29615423 | Oxidative Stress and Diabetic Complications |
| Q93126213 | Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? |
| Q55005264 | Oxidative stress and antioxidant treatment in patients with peripheral artery disease. |
| Q43201615 | Oxidative stress and glucose metabolism--is there a need to revisit effects of insulin treatment? |
| Q35833994 | Oxidative stress in aging human skin |
| Q37455830 | Oxidative stress in diabetes and Alzheimer's disease |
| Q36891939 | Oxidative stress, AGE, and atherosclerosis |
| Q35940134 | PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease |
| Q39223354 | Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter? |
| Q28087462 | Pathogenesis of diabetic cerebral vascular disease complication |
| Q26771860 | Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options |
| Q38111707 | Pathophysiology of the diabetic kidney. |
| Q47803961 | Pattern-recognition receptors: Signaling pathways and dysregulation in canine chronic enteropathies-brief review |
| Q39332869 | Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression |
| Q26782422 | Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease |
| Q37858519 | Pharmacological treatment of diabetic neuropathic pain |
| Q47118391 | Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke |
| Q37423137 | Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction |
| Q40200491 | Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes |
| Q37393702 | Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury |
| Q44504391 | Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. |
| Q56888393 | Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data |
| Q37564791 | Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor |
| Q38460480 | Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies |
| Q37464262 | Postprandial hyperglycemia as an etiological factor in vascular failure |
| Q35607249 | Posttranslationally modified proteins as mediators of sustained intestinal inflammation |
| Q35539571 | Prenatal dietary load of Maillard reaction products combined with postnatal Coca-Cola drinking affects metabolic status of female Wistar rats. |
| Q90397894 | Prevention of Cognitive Decline in Alzheimer's Disease by Novel Antioxidative Supplements |
| Q33783947 | Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells |
| Q59790637 | Promoter methylation cooperates with SNPs to modulate transcription and alter UC risk |
| Q34456143 | Protection of retinal ganglion cells and retinal vasculature by Lycium barbarum polysaccharides in a mouse model of acute ocular hypertension |
| Q92063917 | Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress |
| Q41613567 | Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration |
| Q35752436 | Pulmonary biomarkers based on alterations in protein expression after exposure to arsenic |
| Q38873724 | Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells |
| Q37152947 | RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. |
| Q36209840 | RAGE Deficiency Impairs Bacterial Clearance in Murine Staphylococcal Sepsis, but Has No Significant Impact on Staphylococcal Septic Arthritis |
| Q26744630 | RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage |
| Q60732952 | RAGE Gene Polymorphisms in Patients with Multiple Sclerosis |
| Q42285476 | RAGE Plays a Role in LPS-Induced NF-κB Activation and Endothelial Hyperpermeability |
| Q35888805 | RAGE and AGEs in Mild Cognitive Impairment of Diabetic Patients: A Cross-Sectional Study |
| Q37455857 | RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? |
| Q35970395 | RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells |
| Q36969021 | RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases |
| Q37860348 | RAGE biology, atherosclerosis and diabetes |
| Q43452286 | RAGE blockade and hepatic microcirculation in experimental endotoxaemic liver failure |
| Q34636067 | RAGE controls leukocyte adhesion in preterm and term infants |
| Q57466113 | RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr mice |
| Q36745763 | RAGE gene polymorphism and environmental factor in the risk of oral cancer |
| Q58714432 | RAGE in Cancer Lung: the End of a Long and Winding Road is in Sight |
| Q58597742 | RAGE in the pathophysiology of skeletal muscle |
| Q47325624 | RAGE influences obesity in mice. Effects of the presence of RAGE on weight gain, AGE accumulation, and insulin levels in mice on a high fat diet |
| Q41243867 | RAGE inhibition reduces acute lung injury in mice. |
| Q47867340 | RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity |
| Q34457327 | RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment |
| Q36502858 | RAGE signaling sustains inflammation and promotes tumor development |
| Q24658378 | RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis |
| Q40385373 | RAGE-Mediated Suppression of Interleukin-10 Results in Enhanced Mortality in a Murine Model of Acinetobacter baumannii Sepsis |
| Q39123617 | RAGE-TLR Crosstalk Sustains Chronic Inflammation in Neurodegeneration |
| Q30318035 | RAGE-dependent activation of gene expression of superoxide dismutase and vanins by AGE-rich extracts in mice cardiac tissue and murine cardiac fibroblasts |
| Q24315809 | RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction |
| Q55191109 | RAGE-specific single chain Fv for PET imaging of pancreatic cancer. |
| Q37599419 | RAGE: the beneficial and deleterious effects by diverse mechanisms of actions |
| Q64914593 | Radiological assessment of effectiveness of soluble RAGE in attenuating Angiotensin II-induced LVH mouse model using in vivo 9.4T MRI. |
| Q37665079 | Reactive astrocytes promote adhesive interactions between brain endothelium and endothelial progenitor cells via HMGB1 and beta-2 integrin signaling |
| Q36916192 | Reactive metabolites and AGE-RAGE-mediated inflammation in patients following liver transplantation |
| Q37801791 | Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review |
| Q57825328 | Receptor for Advanced Glycation End Products (RAGE)—Soluble Form (sRAGE) and Gene Polymorphisms in Patients with Breast Cancer |
| Q38182068 | Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases |
| Q37685213 | Receptor for advanced glycation end as drug targets in diabetes-induced skin lesion |
| Q38234624 | Receptor for advanced glycation end products (RAGE) and its ligands: focus on spinal cord injury |
| Q36842628 | Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes |
| Q21285070 | Receptor for advanced glycation end products and its involvement in inflammatory diseases |
| Q33841564 | Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease |
| Q37373486 | Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. |
| Q33873927 | Receptor for advanced glycation endproducts (RAGE) maintains pulmonary structure and regulates the response to cigarette smoke |
| Q37268198 | Receptor for advanced glycation endproducts signaling cascades are activated in pancreatic fibroblasts, but not in the INS1E insulinoma cell line: Are mesenchymal cells major players in chronic inflammation? |
| Q64087511 | Redefining Chronic Inflammation in Aging and Age-Related Diseases: Proposal of the Senoinflammation Concept |
| Q36605862 | Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome |
| Q45970190 | Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population. |
| Q37586657 | Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome |
| Q35674689 | Relationship of Soluble RAGE with Insulin Resistance and Beta Cell Function during Development of Type 2 Diabetes Mellitus |
| Q33733145 | Research on the traditional Chinese medicine treating gastrointestinal motility in diabetic rats by improving biomechanical remodeling and neuroendocrine regulation |
| Q39561253 | Resveratrol-Dependent Down-regulation of Receptor for Advanced Glycation End-products and Oxidative Stress in Kidney of Rats With Diabetes |
| Q28535046 | Retracted: The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice |
| Q47133991 | Role of Galectin-3 in Bone Cell Differentiation, Bone Pathophysiology and Vascular Osteogenesis. |
| Q38547292 | Role of RAGE in Alzheimer's Disease |
| Q27003423 | Role of advanced glycation end products in cellular signaling |
| Q36673607 | Role of oxidative stress in arsenic-induced toxicity. |
| Q46555270 | Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. |
| Q28387007 | S100A12 is up-regulated in pulmonary tuberculosis and predicts the extent of alveolar infiltration on chest radiography: an observational study |
| Q21135467 | S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE) |
| Q28545019 | S100A8/A9 stimulates keratinocyte proliferation in the development of squamous cell carcinoma of the skin via the receptor for advanced glycation-end products |
| Q37629632 | S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? |
| Q39150684 | S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear factor-κB-dependent pathways |
| Q34106243 | S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond |
| Q35708432 | S100B Up-Regulates Macrophage Production of IL1β and CCL22 and Influences Severity of Retinal Inflammation |
| Q34821218 | S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway |
| Q34140133 | S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration |
| Q37051646 | S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages |
| Q48718934 | S100B protein activates a RAGE-dependent autocrine loop in astrocytes: implications for its role in the propagation of reactive gliosis |
| Q36104103 | S100B protein expression in the heart of deceased individuals by overdose: a new forensic marker? |
| Q34606206 | S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release |
| Q37702852 | S100B: a multifunctional role in cardiovascular pathophysiology |
| Q37354472 | S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis |
| Q37300540 | Senescence-dependent impact of anti-RAGE antibody on endotoxemic liver failure |
| Q51342915 | Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects. |
| Q59354444 | Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases |
| Q47390127 | Sevoflurane for Sedation in Acute Respiratory Distress Syndrome. A Randomized Controlled Pilot Study |
| Q91878595 | Shixiang Plaster, a Traditional Chinese Medicine, Promotes Healing in a Rat Model of Diabetic Ulcer Through the receptor for Advanced Glycation End Products (RAGE)/Nuclear Factor kappa B (NF-κB) and Vascular Endothelial Growth Factor (VEGF)/Vascular |
| Q35214629 | Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease |
| Q35949029 | Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies |
| Q35746399 | Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study. |
| Q40126438 | Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein |
| Q37263827 | Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways. |
| Q50880511 | Soluble aggregates of the amyloid-beta protein activate endothelial monolayers for adhesion and subsequent transmigration of monocyte cells. |
| Q64912818 | Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. |
| Q47418383 | Soluble receptor for advanced glycation end products (sRAGE) in tracheobronchial aspirate fluid and cord blood of very low birth weight infants with chorioamnionitis and funisitis |
| Q39636114 | Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation. |
| Q45090317 | Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice |
| Q51620241 | Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. |
| Q35068413 | Soluble receptor for advanced glycation end products as an indicator of pulmonary vascular injury after cardiac surgery |
| Q34564061 | Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality |
| Q55180476 | Soluble receptor for advanced glycation end products in male infertility. |
| Q84010026 | Soy protein prevents renal damage in a fructose-induced model of metabolic syndrome via inhibition of NF-kB in male rats |
| Q39106836 | Statins stimulate the production of a soluble form of the receptor for advanced glycation end products |
| Q24338271 | Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products |
| Q39347827 | Studies on the cardioprotective role of gallic acid against AGE-induced cell proliferation and oxidative stress in H9C2 (2-1) cells |
| Q37377678 | Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin |
| Q91819199 | Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy |
| Q85239968 | Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease |
| Q33783975 | TRB3 mediates advanced glycation end product-induced apoptosis of pancreatic β-cells through the protein kinase C β pathway |
| Q38595544 | Targeting danger-associated molecular patterns after myocardial infarction |
| Q37691594 | Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease |
| Q47988381 | The -374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement |
| Q27664995 | The 1.5 Å Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE) Ectodomains Reveals Unique Features Determining Ligand Binding |
| Q49299877 | The Association Between Variants of Receptor for Advanced Glycation End Products (RAGE) Gene Polymorphisms and Age-Related Macular Degeneration |
| Q41980641 | The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction |
| Q37729333 | The Glyoxalase System and Methylglyoxal-Derived Carbonyl Stress in Sepsis: Glycotoxic Aspects of Sepsis Pathophysiology |
| Q36134557 | The HMGB1 receptor RAGE mediates ischemic brain damage |
| Q33745462 | The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation |
| Q47176251 | The HMGB1/RAGE Pro-Inflammatory Axis in the Human Placenta: Modulating Effect of Low Molecular Weight Heparin. |
| Q30505780 | The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. |
| Q37141580 | The Immunoproteasome in oxidative stress, aging, and disease. |
| Q90221533 | The Impact of Diabetic Conditions and AGE/RAGE Signaling on Cardiac Fibroblast Migration |
| Q90440117 | The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for Inflammatory Bowel Diseases |
| Q97519022 | The Receptor for Advanced Glycation Endproducts (RAGE) Contributes to Severe Inflammatory Liver Injury in Mice |
| Q36146033 | The Role of Neutrophil Proteins on the Amyloid Beta-RAGE Axis. |
| Q36057340 | The Role of receptor for Advanced Glycation End Products (RAGE) in the proliferation of hepatocellular carcinoma |
| Q37066216 | The action of aminoguanidine on the liver of trained diabetic rats |
| Q38086654 | The beneficial role of thiamine in Parkinson disease. |
| Q33851482 | The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation |
| Q51887196 | The developmental aging and origins of health and disease hypotheses explained by different protein networks. |
| Q34335614 | The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia |
| Q42849056 | The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions |
| Q35617622 | The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. |
| Q80517354 | The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas |
| Q45885546 | The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease |
| Q21202840 | The generation and function of soluble apoE receptors in the CNS |
| Q34020798 | The glomerulus--a view from the outside--the podocyte |
| Q40112947 | The impact of RAGE inhibition in animal models of bacterial sepsis: a systematic review and meta-analysis |
| Q89584286 | The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines |
| Q37158848 | The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. |
| Q26801586 | The neurotoxic effects of vitamin A and retinoids |
| Q36800611 | The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice |
| Q57718003 | The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood |
| Q37212720 | The receptor RAGE: Bridging inflammation and cancer |
| Q38025026 | The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome |
| Q36199320 | The receptor for advanced glycation end products impairs collateral formation in both diabetic and non-diabetic mice |
| Q93208374 | The receptor for advanced glycation end-products enhances lung epithelial wound repair: An in vitro study |
| Q37140804 | The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation |
| Q94476127 | The role of innate immunity in the long-term outcome of lung transplantation |
| Q58701069 | The role of neutrophil granule proteins in neuroinflammation and Alzheimer's disease |
| Q38074422 | The role of vitamin D in Alzheimer's disease: possible genetic and cell signaling mechanisms |
| Q37307799 | Theories, types and treatments of diabetic neuropathy |
| Q92343798 | Therapeutic Potential of Lespedeza bicolor to Prevent Methylglyoxal-Induced Glucotoxicity in Familiar Diabetic Nephropathy |
| Q28582962 | Total and mitochondrial nitrosative stress, decreased brain-derived neurotrophic factor (BDNF) levels and glutamate uptake, and evidence of endoplasmic reticulum stress in the hippocampus of vitamin A-treated rats |
| Q37716694 | Trends in advanced glycation end products research in diabetes mellitus and its complications. |
| Q35137159 | Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis |
| Q57118512 | Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats |
| Q51863701 | Up-regulation of receptors for advanced glycation end-products by alveolar epithelium influences cytodifferentiation and causes severe lung hypoplasia. |
| Q33867705 | Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus |
| Q42330303 | Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway |
| Q43172749 | Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-κB pathway activation. |
| Q38041671 | VEGF and podocytes in diabetic nephropathy |
| Q28081090 | Vascular Effects of Dietary Advanced Glycation End Products |
| Q37636453 | Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms |
| Q35676892 | Vitamin D Levels Decline with Rising Number of Cardiometabolic Risk Factors in Healthy Adults: Association with Adipokines, Inflammation, Oxidative Stress and Advanced Glycation Markers |
| Q39052240 | sRAGE in septic shock: a potential biomarker of mortality |
Search more.